1. Home
  2. WOLF vs OMER Comparison

WOLF vs OMER Comparison

Compare WOLF & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WOLF
  • OMER
  • Stock Information
  • Founded
  • WOLF 1987
  • OMER 1994
  • Country
  • WOLF United States
  • OMER United States
  • Employees
  • WOLF N/A
  • OMER N/A
  • Industry
  • WOLF Semiconductors
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • WOLF Technology
  • OMER Health Care
  • Exchange
  • WOLF Nasdaq
  • OMER Nasdaq
  • Market Cap
  • WOLF 200.8M
  • OMER 188.1M
  • IPO Year
  • WOLF 1993
  • OMER 2009
  • Fundamental
  • Price
  • WOLF $1.55
  • OMER $3.42
  • Analyst Decision
  • WOLF Hold
  • OMER Strong Buy
  • Analyst Count
  • WOLF 13
  • OMER 5
  • Target Price
  • WOLF $10.67
  • OMER $18.00
  • AVG Volume (30 Days)
  • WOLF 154.0M
  • OMER 968.1K
  • Earning Date
  • WOLF 08-20-2025
  • OMER 08-06-2025
  • Dividend Yield
  • WOLF N/A
  • OMER N/A
  • EPS Growth
  • WOLF N/A
  • OMER N/A
  • EPS
  • WOLF N/A
  • OMER N/A
  • Revenue
  • WOLF $761,300,000.00
  • OMER N/A
  • Revenue This Year
  • WOLF N/A
  • OMER N/A
  • Revenue Next Year
  • WOLF $14.42
  • OMER $3,446.91
  • P/E Ratio
  • WOLF N/A
  • OMER N/A
  • Revenue Growth
  • WOLF N/A
  • OMER N/A
  • 52 Week Low
  • WOLF $0.39
  • OMER $2.95
  • 52 Week High
  • WOLF $3.33
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • WOLF 49.56
  • OMER 49.27
  • Support Level
  • WOLF $1.38
  • OMER $3.41
  • Resistance Level
  • WOLF $1.77
  • OMER $4.02
  • Average True Range (ATR)
  • WOLF 0.44
  • OMER 0.25
  • MACD
  • WOLF 0.06
  • OMER 0.08
  • Stochastic Oscillator
  • WOLF 35.38
  • OMER 50.00

About WOLF Wolfspeed Inc.

Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: